Related Experiment Video
Updated: Jul 21, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Parneet K Cheema1,2, Shantanu O Banerji3, Normand Blais4
1Division of Medical Oncology, William Osler Health System, University of Toronto, Brampton, ON L6R 3J7, Canada.
KRAS G12C mutations drive non-small cell lung cancer. Sotorasib is recommended for advanced NSCLC patients who progressed on standard care, with liver monitoring advised.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Activating KRAS G12C mutations are common in non-small cell lung cancer (NSCLC).
- Novel KRAS G12C inhibitors are emerging, necessitating clinical guidance.
- Sotorasib, a KRAS G12C inhibitor, is approved in Canada.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Ras Gene
Ras is a...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers